• Immunocore published a Phase 1 presentation evaluating brenetafusp alone or with tebentafusp in metastatic uveal melanoma.
• The first-line combination cohort of 17 patients achieved a 29% response rate; median progression-free survival was 8.1 months.
• Two-year overall survival reached 70%, with median survival follow-up of 29 months.
• Combination treatment showed no new safety signals; no treatment-related adverse events caused discontinuation or death across either treatment group.
• The findings support further evaluation in DUET-UVEAL, a randomized Phase 2/3 study in planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.